Artelo Biosciences (Nasdaq: ARTL) plans 3-for-1 reverse stock split in March 2026

Rhea-AI Filing Summary

Artelo Biosciences approved a 3-for-1 reverse stock split of its common stock, combining each three existing shares into one new share. The split is intended to increase the share price to improve marketability and liquidity, with trading on a split-adjusted basis starting March 10, 2026.

No fractional shares will be issued; holders otherwise entitled to a fraction will receive one whole share instead. The company expects approximately 708,258 shares of common stock to be issued and outstanding immediately after the reverse split, and all outstanding warrants and other derivatives will adjust automatically under their terms.

Insights

Equity structure analyst

Artelo is consolidating shares 3-for-1 to lift its stock price while keeping ownership percentages the same.

The 3-for-1 reverse split means every three existing shares become one new share, with no change to each investor’s proportional ownership. Reverse splits are often used by companies seeking a higher per-share price and to support continued exchange listing.

The company states that all outstanding warrants and other derivatives will adjust automatically, which helps keep capital structure terms aligned. Investors can look to future filings, including the referenced Form 8-K, for any additional details about listing requirements or subsequent capital actions.

EXHIBIT 99.1

Artelo Biosciences Announces Reverse Stock Split

Shares Expected to Begin Trading on a Split-Adjusted Basis on March 10, 2026

SOLANA BEACH, CA – March 6, 2026 – Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced that on February 27, 2026, Artelo’s Board of Directors approved a 3-for-1 reverse stock split (“Reverse Split”) of the Company’s common stock (“Common Stock”). The Company’s common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open, March 10, 2026. The Board of Directors determined the 3-for-1 ratio to be appropriate in order to increase the price per share of the Common Stock to improve its marketability and liquidity. The new CUSIP number for the Common Stock following the Reverse Split will be 04301G706.

As a result of the Reverse Split, each three shares of the Company’s issued and outstanding Common Stock will be automatically combined and converted into one issued and outstanding share of Common Stock. No fractional shares will be issued as a result of the Reverse Split. Stockholders who otherwise would be entitled to a fractional share because they hold a number of shares not evenly divisible by the 3-for-1 ratio will automatically be entitled to receive one whole share of Common Stock for each such fractional share. Each shareholder’s pro-rata percentage ownership will remain unchanged as a result of the reverse split and no further action is required by shareholders. All of the Company’s current outstanding warrants to purchase shares of Common Stock and other derivatives automatically adjust per their terms to reflect the reverse split. Immediately after the reverse split becomes effective, there will be approximately 708,258 shares of Common Stock issued and outstanding. For further details, all shareholders are invited to review the 8-K regarding this reverse split which will be filed March 6, 2026.

About Artelo Biosciences

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, commercial, and treasury management practices, including digital assets, to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.

1

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:

Crescendo Communications, LLC

Tel: 212-671-1020

Email: ARTL@crescendo-ir.com

2

FAQ

What reverse stock split did Artelo Biosciences (ARTL) approve?

Artelo Biosciences approved a 3-for-1 reverse stock split of its common stock. Every three existing shares will automatically combine into one new share, aiming to raise the share price and improve marketability and liquidity without changing each investor’s proportional ownership.

When will Artelo Biosciences (ARTL) begin trading on a split-adjusted basis?

Artelo Biosciences shares are expected to begin trading on a split-adjusted basis on March 10, 2026. From the market open that day, Nasdaq Capital Market quotations will reflect the 3-for-1 reverse stock split and the company’s new, lower share count.

How will fractional shares be handled in the Artelo Biosciences reverse split?

Artelo Biosciences will not issue fractional shares in the reverse split. Any stockholder who would otherwise receive a fractional share because their holdings are not divisible by three will instead automatically receive one whole share of common stock for that fractional entitlement.

How many Artelo Biosciences (ARTL) shares will be outstanding after the reverse split?

Immediately after the 3-for-1 reverse split becomes effective, Artelo Biosciences expects approximately 708,258 shares of common stock to be issued and outstanding. This reduced share count reflects the consolidation of every three existing shares into one new share.

Will Artelo Biosciences warrants and derivatives change after the reverse split?

All of Artelo Biosciences’ outstanding warrants and other derivatives tied to common stock will automatically adjust under their existing terms. These adjustments are designed to reflect the 3-for-1 reverse split ratio while preserving the economic relationships embedded in those instruments.

Why is Artelo Biosciences (ARTL) implementing a reverse stock split?

Artelo Biosciences’ board determined the 3-for-1 reverse split was appropriate to increase the price per share of its common stock. The company states this is intended to improve the stock’s marketability and liquidity while keeping each shareholder’s pro-rata ownership percentage unchanged.

Filing Exhibits & Attachments

7 documents

Press Releases

• EX-99.1 PRESS RELEASE 8.8 KB

Other Documents

• EX-3.1 CERTIFICATE OF CHANGE 922 B
• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 4.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 15.4 KB
• EX-101 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE 898 B
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 9.8 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 2.0 KB